MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

Search

Royalty Pharma PLC (Class A)

Geschlossen

BrancheGesundheitswesen

31.79 1.6

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

30.97

Max

31.84

Schlüsselkennzahlen

By Trading Economics

Einkommen

441M

334M

Verkäufe

29M

594M

KGV

Branchendurchschnitt

16.298

63.778

EPS

1.151

Dividendenrendite

2.83

Gewinnspanne

56.288

EBITDA

-511M

362M

Empfehlungen

By TipRanks

Empfehlungen

Starkes Kaufsignal

12-Monats-Prognose

+22.54% upside

Dividenden

By Dow Jones

Dividendenrendite

Branchendurchschnitt

2.83%

2.39%

Nächstes Ergebnis

8. Mai 2025

Nächste Dividendenausschüttung

13. Juni 2025

Nächstes Ex-Dividendendatum

15. Mai 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

18B

Vorheriger Eröffnungskurs

30.19

Vorheriger Schlusskurs

31.79

Nachrichtenstimmung

By Acuity

50%

50%

166 / 386 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Strong Bearish Evidence

Royalty Pharma PLC (Class A) Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

3. Apr. 2025, 23:04 UTC

Top News

JPMorgan Raises Risk of U.S., Global Recession to 60%

3. Apr. 2025, 22:40 UTC

Wichtige Markttreiber

Aldeyra Shares Fall on FDA Complete Response Letter for Dry Eye Disease Drug

3. Apr. 2025, 22:18 UTC

Akquisitionen, Fusionen, Übernahmen

Quantum Corp. Gets Strategic Investment, Names New Financial Chief

3. Apr. 2025, 18:51 UTC

Akquisitionen, Fusionen, Übernahmen

Capital One, Discover Merger Clears Regulatory Hurdle, Sources Tell The New York Times

3. Apr. 2025, 23:43 UTC

Market Talk

Gold Steady, Supported by Potential Safe-Haven Demand -- Market Talk

3. Apr. 2025, 23:41 UTC

Market Talk

Nikkei May Fall as U.S. Tariffs Raise Concerns About Global Growth -- Market Talk

3. Apr. 2025, 22:22 UTC

Akquisitionen, Fusionen, Übernahmen

Is TikTok Getting Banned? What to Expect as the Deadline Approaches. -- Barrons.com

3. Apr. 2025, 22:21 UTC

Akquisitionen, Fusionen, Übernahmen

Is TikTok Getting Banned? What to Expect as the Deadline Approaches. -- Barrons.com

3. Apr. 2025, 21:43 UTC

Top News
Ergebnisse

The Day Trump's Tariffs Shook Wall Street and Corporate America -- 5th Update

3. Apr. 2025, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

3. Apr. 2025, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

3. Apr. 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

3. Apr. 2025, 20:43 UTC

Market Talk

Plummeting Toronto Home Sales Reflect Trade, Political Uncertainty -- Market Talk

3. Apr. 2025, 20:34 UTC

Top News

Trump's Tariffs Were Supposed to Boost the Dollar, But Here's Why the Opposite Happened -- Heard on the Street -- 2nd Update

3. Apr. 2025, 20:23 UTC

Top News

Trump Tariffs Send Dow Industrials to 1600-Point Decline; Dollar Slumps -- WSJ

3. Apr. 2025, 20:15 UTC

Akquisitionen, Fusionen, Übernahmen

Blackstone Life Sciences And Anthos Therapeutics Announce Novartis Has Completed The Acquisition Of Anthos Therapeutics In A Deal Valued At Up To $3.1B, With $925M Paid Upfront >BX

3. Apr. 2025, 19:55 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

3. Apr. 2025, 19:55 UTC

Market Talk

Dollar Weakens as Investors Seek Safety Elsewhere -- Market Talk

3. Apr. 2025, 19:21 UTC

Market Talk

Oil Futures Slide on U.S. Tariffs, OPEC+ Output Plan -- Market Talk

3. Apr. 2025, 19:15 UTC

Market Talk

U.S. Natural Gas Stays Focused on Weather, Storage -- Market Talk

3. Apr. 2025, 18:45 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

3. Apr. 2025, 18:45 UTC

Market Talk

Gold Drops In Tariff Fallout -- Market Talk

3. Apr. 2025, 18:39 UTC

Market Talk

U.S. Tariffs Could Give Natural Gas Edge Over Solar -- Market Talk

3. Apr. 2025, 18:38 UTC

Top News

Trump Tariffs Send Dow Industrials to 1400-Point Decline; Dollar Slumps -- WSJ

3. Apr. 2025, 18:30 UTC

Top News

Auto Industry Braces for Major Pain From Trump's Tariffs -- Analysis

3. Apr. 2025, 18:20 UTC

Market Talk

Uncertainty Still Roils Companies in Tariff Saga -- Market Talk

3. Apr. 2025, 18:18 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

3. Apr. 2025, 18:17 UTC

Market Talk

U.S. Workers Can't Match International Labor as Companies Consider Moving Supply Chains -- Market Talk

3. Apr. 2025, 18:04 UTC

Market Talk

US Sees More Job Openings in Construction, Transportation -- Market Talk

3. Apr. 2025, 17:55 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

Peer-Vergleich

Kursveränderung

Royalty Pharma PLC (Class A) Prognose

Kursziel

By TipRanks

22.54% Vorteil

12-Monats-Prognose

Durchschnitt 38.33 USD  22.54%

Hoch 42 USD

Tief 33 USD

Basierend auf 4 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Royalty Pharma PLC (Class A) – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

4 ratings

3

Buy

1

Halten

0

Sell

Technischer Score

By Trading Central

31.38 / 33.695Unterstützung & Widerstand

Kurzfristig

Strong Bearish Evidence

Mittelfristig

Strong Bearish Evidence

Langfristig

Bullish Evidence

Stimmung

By Acuity

166 / 386 Ranking in Gesundheitswesen

Nachrichtenstimmung

Neutral

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Durchschnitt

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Royalty Pharma PLC (Class A)

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 commercial products and 14 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neuroscience, immunology, respiratory, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.